Madrigal's Rezdiffra off to strong start, but 'bumpiness' is coming: analyst

In its first full quarter on the market, Madrigal Pharmaceuticals’ Rezdiffra, the first treatment for metabolic dysfunction-associated steatohepatitis (MASH), achieved sales of $14.6 million. The company also reported that by the end of the second quarter, there were 2,000 patients on Rezdiffra, in a promising launch for the liver disease drug.